secwatch.observer — SEC 8-K summary
======================================

Issuer:     EyePoint, Inc. (EYPT)
CIK:        0001314102
Form:       8-K
Filed at:   2025-07-29T23:59:59+00:00
Accession:  0000950170-25-099383
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

EyePoint finishes Phase 3 enrollment for DURAVYU in wet AMD; top-line data mid-2026
--------------------------------------------------------------------------------

- LUCIA trial enrolled and randomized over 400 patients in seven months; total >800 across both trials.
- Interim safety data consistent with prior DURAVYU trials; DSMC recommended continuation without protocol changes.
- Topline 56-week data for LUGANO expected mid-2026; LUCIA data to follow shortly after.
- DURAVYU is a sustained-release TKI for wet AMD; Phase 3 program aligned with FDA and EMA.
- DURAVYU has been evaluated in over 190 patients across four trials with favorable safety profile.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1314102/000095017025099383/0000950170-25-099383-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1314102/000095017025099383/eypt-20250729.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-099383

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer